Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults.
about
A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderlyThe role of vaccination in preventing pneumococcal disease in adultsRandomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adultsThe management of community-acquired pneumonia in the elderlyAn Australian audit of vaccination status in children and adolescents with inflammatory bowel diseaseRecommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe.Assessment of vaccine candidates for persons aged 50 and older: a review.Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?Serotype distribution in non-bacteremic pneumococcal pneumonia: association with disease severity and implications for pneumococcal conjugate vaccinesThe majority of adult pneumococcal invasive infections in Portugal are still potentially vaccine preventable in spite of significant declines of serotypes 1 and 5.Rationale and design of the costs, health status and outcomes in community-acquired pneumonia (CHO-CAP) study in elderly persons hospitalized with CAPA randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly.The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study.Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cellsSafety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly.Potential effect of PCV13 introduction on Emergency Department accesses for lower respiratory tract infections in elderly and at risk adults.Hospitalization costs for community-acquired pneumonia in Dutch elderly: an observational studyImmunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adultsThe impact of community-acquired pneumonia on the health-related quality-of-life in elderlyVaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysisLong-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.Pneumonia immunization in older adults: review of vaccine effectiveness and strategiesModeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults.Balancing the Efficacy and Safety of Vaccines in the Elderly.Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.Risk factors for community-acquired pneumonia in adults in Europe: a literature review.Theory and strategy for Pneumococcal vaccines in the elderly.Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.Quality of life in community-dwelling Dutch elderly measured by EQ-5D-3L.Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in SingaporeAdvances in the prevention, management, and treatment of community-acquired pneumoniaThe stubborn persistence of adult pneumococcal pneumonia as a public health problem.Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23.Pneumococcal conjugate vaccination for older adults: Reply letter to Hollingsworth et al.Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly.
P2860
Q26999313-3C06A332-9EA8-4EB7-8E01-0CDEC94641A8Q28396749-3C89C62B-05EC-4935-BA79-153CEEF5789FQ33601853-96B10BA1-A428-466F-A9C5-5AA5ACBEA825Q33915736-35D33022-B538-4AB7-A830-90B41CEC299AQ33974382-6CE50227-40A4-4E34-AA3A-EC7E3865FF14Q34402444-D7E9CE09-1DBB-4DA2-87A2-BA4508942DA1Q34668826-B732D270-8C54-40AF-BE3E-CF13206C19FFQ34798448-8F91EF4A-AB10-41C1-A8D2-7755A1980C93Q34979620-FC09188D-2F30-456E-A510-18F704409963Q34997063-28E45F82-1894-43ED-AC86-C03256872D50Q35071890-FF7D545D-E151-4904-A5A7-4137A847D1ADQ35156164-5362DB67-AB3C-4C7B-8C76-424CE48BA1A6Q35231034-0F504E5B-366E-4863-A4D5-2569BE966005Q35855959-40A0000B-779D-42D1-88A7-7130CCE11E50Q35883435-8A0E57E7-0AAE-4E25-A9D4-F785112DFC45Q35886979-D766B4D4-AB94-41F0-B34A-131BEB95A975Q35887032-F6A2D04B-6C40-419E-9355-F4068DBF9A86Q36121879-3508184E-28D5-4550-ABBC-8BAB9AD9E45EQ36255837-C3FE75BA-35CC-414F-92B5-A1B593096B22Q36307771-B17C6070-99B7-446A-9A19-7DFB466137E9Q36350368-2C1D1DCD-AEEA-4EFD-A6A0-EB090B01DE38Q36379580-64E28C84-AD0D-4ABB-B5F1-378A5EAD22F0Q36393396-B64CB37A-ED8A-4E0F-AD38-C42F636E2EA7Q36696287-239080CE-DAE2-4B9E-9583-09FCFBFB7EFEQ36740019-E16632AE-302D-4685-B3A4-046C4A575553Q37092845-BC2EE7BC-D55F-48BE-9AD7-617956A5EC27Q37267627-8E31A2E8-7CF0-48D0-9B59-DBF3FAA062E7Q37309215-6CB744E6-B9D3-463A-BCEB-9CA2D843C789Q37478401-D7574EF8-A5D1-4FCB-BD2D-34D73B946EAEQ37572143-A8B97344-4EFF-43C1-B98F-95A4B3E7CBC3Q37584878-9770DC09-1298-4500-AB58-C67DE2D3DB43Q37685565-456DAFEE-B6B5-4972-9C3D-90E56A8B1196Q37822666-8186E072-5C7D-4A2C-998E-2585E112F4E4Q42738526-6C05BB5C-56FC-4C21-AB53-8AD909C54038Q42738528-E121888E-4B3C-4571-B2F3-5CA6BD3D8C67Q42923024-C57974FC-1B4A-4131-86A2-A6446233DE7DQ54994810-58F498C9-ECAE-438C-AA04-FD2AE46CE89AQ55267236-D7AFDD3D-7118-428F-B6B9-DB562CBE71AB
P2860
Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rationale and design of CAPITA ...... e efficacy among older adults.
@en
Rationale and design of CAPITA ...... e efficacy among older adults.
@nl
type
label
Rationale and design of CAPITA ...... e efficacy among older adults.
@en
Rationale and design of CAPITA ...... e efficacy among older adults.
@nl
prefLabel
Rationale and design of CAPITA ...... e efficacy among older adults.
@en
Rationale and design of CAPITA ...... e efficacy among older adults.
@nl
P2093
P1476
Rationale and design of CAPITA ...... e efficacy among older adults.
@en
P2093
Bolkenbaas M
Grobbee DE
McDonough A
Patterson S
Sanders EA
P304
P577
2008-10-01T00:00:00Z